Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 3
2014 4
2015 1
2016 2
2017 1
2018 1
2019 3
2020 6
2021 3
2022 5
2023 10
2024 2
2025 9
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.
Schimmer R, Klemm N, Fullin J, Topcu E, Treacy M, Zielinska K, Doerdelmann C, Devesa-Serrano D, Lock M, Caiado F, Koch C, Dietliker N, Schwotzer R, Buehler MM, Myllymäki M, Kurppa KJ, Manz MG, Lopes M, Boettcher S. Schimmer R, et al. Among authors: boettcher s. Blood. 2026 Jan 5:blood.2025030230. doi: 10.1182/blood.2025030230. Online ahead of print. Blood. 2026. PMID: 41490322
The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.
Fullin J, Topçu E, Zielińska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Bühler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S. Fullin J, et al. Among authors: boettcher s. Leukemia. 2026 Feb;40(2):279-292. doi: 10.1038/s41375-025-02839-5. Epub 2025 Dec 17. Leukemia. 2026. PMID: 41407825 Free PMC article.
TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.
Pottier A, Park S, Lee Y, Liccardo F, Yang H, Park J, Lorant A, Schnekenburger M, Brusa D, Li V, Valente S, Mai A, Skuli SJ, Carroll M, Boettcher S, Sarry JE, Cerella C, Morceau F, Diederich M. Pottier A, et al. Among authors: boettcher s. Cancer Lett. 2025 Sep 1;633:218011. doi: 10.1016/j.canlet.2025.218011. Online ahead of print. Cancer Lett. 2025. PMID: 40902843 Free article.
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Skuli SJ, et al. Among authors: boettcher s. Leukemia. 2025 Sep;39(9):2087-2098. doi: 10.1038/s41375-025-02668-6. Epub 2025 Jul 9. Leukemia. 2025. PMID: 40634510 Free PMC article.
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M. Carter BZ, et al. Among authors: boettcher s. Blood. 2025 Nov 20;146(21):2574-2588. doi: 10.1182/blood.2025028935. Blood. 2025. PMID: 40608889 Free PMC article.
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Fiskus W, et al. Among authors: boettcher s. Blood Cancer J. 2025 May 21;15(1):99. doi: 10.1038/s41408-025-01306-9. Blood Cancer J. 2025. PMID: 40399254 Free PMC article. No abstract available.
Endothelial CCR2 Signaling Induced by Colon Carcinoma Cells Enables Extravasation via the JAK2-Stat5 and p38MAPK Pathway.
Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Wolf MJ, et al. Among authors: boettcher s. Cancer Cell. 2025 May 12;43(5):988-992. doi: 10.1016/j.ccell.2025.04.012. Cancer Cell. 2025. PMID: 40359909 No abstract available.
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.
Klemm N, Schimmer RR, Konrad NK, Thelen F, Fullin J, Topçu E, Koch C, Treacy M, Leventhal MJ, Bühler MM, Lysenko V, Theocharides APA, Kurppa KJ, Balabanov S, Baubec T, Krivtsov AV, Miller PG, Armstrong SA, Ebert BL, Manz MG, Nombela-Arrieta C, Boettcher S. Klemm N, et al. Among authors: boettcher s. Cancer Res. 2025 Jun 2;85(11):1978-1996. doi: 10.1158/0008-5472.CAN-24-1136. Cancer Res. 2025. PMID: 40163352 Free PMC article.
Prolonged persistence of mutagenic DNA lesions in somatic cells.
Spencer Chapman M, Mitchell E, Yoshida K, Williams N, Fabre MA, Ranzoni AM, Robinson PS, Kregar LD, Wilk M, Boettcher S, Mahbubani K, Saeb Parsy K, Gowers KHC, Janes SM, Ng SWK, Hoare M, Green AR, Vassiliou GS, Cvejic A, Manz MG, Laurenti E, Martincorena I, Stratton MR, Nangalia J, Coorens THH, Campbell PJ. Spencer Chapman M, et al. Among authors: boettcher s. Nature. 2025 Feb;638(8051):729-738. doi: 10.1038/s41586-024-08423-8. Epub 2025 Jan 15. Nature. 2025. PMID: 39814886 Free PMC article.
Clonal dynamics after allogeneic haematopoietic cell transplantation.
Spencer Chapman M, Wilk CM, Boettcher S, Mitchell E, Dawson K, Williams N, Müller J, Kovtonyuk L, Jung H, Caiado F, Roberts K, O'Neill L, Kent DG, Green AR, Nangalia J, Manz MG, Campbell PJ. Spencer Chapman M, et al. Among authors: boettcher s. Nature. 2024 Nov;635(8040):926-934. doi: 10.1038/s41586-024-08128-y. Epub 2024 Oct 30. Nature. 2024. PMID: 39478227 Free PMC article.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. Mueller J, et al. Among authors: boettcher s. EMBO Mol Med. 2024 Mar;16(3):445-474. doi: 10.1038/s44321-024-00024-2. Epub 2024 Feb 14. EMBO Mol Med. 2024. PMID: 38355749 Free PMC article.
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.
Wilk CM, Cathomas F, Török O, Le Berichel J, Park MD, Bigenwald C, Heaton GR, Hamon P, Troncoso L, Scull BP, Dangoor D, Silvin A, Fleischmann R, Belabed M, Lin H, Merad Taouli E, Boettcher S, Li L, Aubry A, Manz MG, Kofler JK, Yue Z, Lira SA, Ginhoux F, Crary JF, McClain KL, Picarsic JL, Russo SJ, Allen CE, Merad M. Wilk CM, et al. Among authors: boettcher s. Immunity. 2023 Dec 12;56(12):2790-2802.e6. doi: 10.1016/j.immuni.2023.11.011. Immunity. 2023. PMID: 38091952 Free PMC article.
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Nishida Y, et al. Among authors: boettcher s. Sci Adv. 2023 Dec;9(48):eadh1436. doi: 10.1126/sciadv.adh1436. Epub 2023 Nov 29. Sci Adv. 2023. PMID: 38019903 Free PMC article.
Circulating senescent myeloid cells drive blood brain barrier breakdown and neurodegeneration.
Wilk CM, Cathomas F, Török O, Le Berichel J, Park MD, Heaton GR, Hamon P, Troncoso L, Scull BP, Dangoor D, Silvin A, Fleischmann R, Belabed M, Lin H, Taouli EM, Boettcher S, Manz MG, Kofler JK, Yue Z, Lira SA, Ginhoux F, Crary JF, McClain KL, Picarsic JL, Russo SJ, Allen CE, Merad M. Wilk CM, et al. Among authors: boettcher s. bioRxiv [Preprint]. 2023 Oct 11:2023.10.10.561744. doi: 10.1101/2023.10.10.561744. bioRxiv. 2023. Update in: Immunity. 2023 Dec 12;56(12):2790-2802.e6. doi: 10.1016/j.immuni.2023.11.011. PMID: 37873371 Free PMC article. Updated. Preprint.
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
Miller PG, Sperling AS, Mayerhofer C, McConkey ME, Ellegast JM, Da Silva C, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter I, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL. Miller PG, et al. Among authors: boettcher s. Blood. 2023 Dec 14;142(24):2079-2091. doi: 10.1182/blood.2023020331. Blood. 2023. PMID: 37595362 Free PMC article.
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.
Marion W, Koppe T, Chen CC, Wang D, Frenis K, Fierstein S, Sensharma P, Aumais O, Peters M, Ruiz-Torres S, Chihanga T, Boettcher S, Shimamura A, Bauer DE, Schlaeger T, Wells SI, Ebert BL, Starczynowski D, da Rocha EL, Rowe RG. Marion W, et al. Among authors: boettcher s. Leukemia. 2023 Aug;37(8):1698-1708. doi: 10.1038/s41375-023-01945-6. Epub 2023 Jun 30. Leukemia. 2023. PMID: 37391485 Free PMC article.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Carter BZ, et al. Among authors: boettcher s. Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047. Blood. 2023. PMID: 37339579 Free PMC article.
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: boettcher s. Blood Cancer J. 2023 May 17;13(1):80. doi: 10.1038/s41408-023-00857-z. Blood Cancer J. 2023. PMID: 37193700 Free PMC article. No abstract available.
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Among authors: boettcher s. Blood Cancer J. 2023 Apr 24;13(1):57. doi: 10.1038/s41408-023-00830-w. Blood Cancer J. 2023. PMID: 37088806 Free PMC article.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Fiskus W, et al. Among authors: boettcher s. Blood Cancer J. 2023 Apr 13;13(1):53. doi: 10.1038/s41408-023-00826-6. Blood Cancer J. 2023. PMID: 37055414 Free PMC article.
Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.
Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Caiado F, et al. Among authors: boettcher s. Blood. 2023 Feb 23;141(8):886-903. doi: 10.1182/blood.2022016835. Blood. 2023. PMID: 36379023 Free PMC article.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Fiskus W, et al. Among authors: boettcher s. Leukemia. 2022 Nov;36(11):2729-2733. doi: 10.1038/s41375-022-01707-w. Epub 2022 Sep 23. Leukemia. 2022. PMID: 36151141 Free PMC article. No abstract available.
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells.
Sellar RS, Sperling AS, Słabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, Dutta RK, Boettcher S, Lin AE, Sandoval B, Quevedo Barrios VA, Kovalcik V, Koeppel J, Henderson EK, Fink EC, Yang L, Chan A, Pokharel SP, Bergstrom EJ, Burt R, Udeshi ND, Carr SA, Fischer ES, Chen CW, Ebert BL. Sellar RS, et al. Among authors: boettcher s. J Clin Invest. 2022 Aug 15;132(16):e153514. doi: 10.1172/JCI153514. J Clin Invest. 2022. PMID: 35763353 Free PMC article.
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
Kennedy AL, Myers KC, Bowman J, Gibson CJ, Camarda ND, Furutani E, Muscato GM, Klein RH, Ballotti K, Liu S, Harris CE, Galvin A, Malsch M, Dale D, Gansner JM, Nakano TA, Bertuch A, Vlachos A, Lipton JM, Castillo P, Connelly J, Churpek J, Edwards JR, Hijiya N, Ho RH, Hofmann I, Huang JN, Keel S, Lamble A, Lau BW, Norkin M, Stieglitz E, Stock W, Walkovich K, Boettcher S, Brendel C, Fleming MD, Davies SM, Weller EA, Bahl C, Carter SL, Shimamura A, Lindsley RC. Kennedy AL, et al. Among authors: boettcher s. Nat Commun. 2021 Feb 26;12(1):1334. doi: 10.1038/s41467-021-21588-4. Nat Commun. 2021. PMID: 33637765 Free PMC article.
An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation.
Marion W, Boettcher S, Ruiz-Torres S, Lummertz da Rocha E, Lundin V, Morris V, Chou S, Zhao AM, Kubaczka C, Aumais O, Zhang Y, Shimamura A, Schlaeger TM, North TE, Ebert BL, Wells SI, Daley GQ, Rowe RG. Marion W, et al. Among authors: boettcher s. Blood Adv. 2020 Oct 13;4(19):4679-4692. doi: 10.1182/bloodadvances.2020001593. Blood Adv. 2020. PMID: 33002135 Free PMC article.
Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID-19.
Hameister E, Stolz SM, Fuhrer Y, Thienemann F, Schaer DJ, Nemeth J, Schuepbach RA, Goede J, Reinhart S, Schmidt A, Kahraman A, Schmid M, Moch H, Zoche M, Manz MG, Balabanov S, Boettcher S. Hameister E, et al. Among authors: boettcher s. Hemasphere. 2020 Aug 10;4(4):e453. doi: 10.1097/HS9.0000000000000453. eCollection 2020 Aug. Hemasphere. 2020. PMID: 32885145 Free PMC article. No abstract available.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al Ali NH, Lancet JE, Cleveland JL, Padron E, List AF. Sallman DA, et al. Among authors: boettcher s. Blood. 2020 Dec 10;136(24):2812-2823. doi: 10.1182/blood.2020006158. Blood. 2020. PMID: 32730593 Free PMC article.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA. Kurppa KJ, et al. Among authors: boettcher s. Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006. Cancer Cell. 2020. PMID: 31935369 Free PMC article.
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. Boettcher S, et al. Science. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649. Science. 2019. PMID: 31395785 Free PMC article.
Clonal Hematopoiesis of Indeterminate Potential.
Boettcher S, Ebert BL. Boettcher S, et al. J Clin Oncol. 2019 Feb 10;37(5):419-422. doi: 10.1200/JCO.2018.79.3588. Epub 2018 Dec 27. J Clin Oncol. 2019. PMID: 30589599 No abstract available.
A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformation.
Sievert H, Pällmann N, Miller KK, Hermans-Borgmeyer I, Venz S, Sendoel A, Preukschas M, Schweizer M, Boettcher S, Janiesch PC, Streichert T, Walther R, Hengartner MO, Manz MG, Brümmendorf TH, Bokemeyer C, Braig M, Hauber J, Duncan KE, Balabanov S. Sievert H, et al. Among authors: boettcher s. Dis Model Mech. 2014 Aug;7(8):963-76. doi: 10.1242/dmm.014449. Epub 2014 May 15. Dis Model Mech. 2014. PMID: 24832488 Free PMC article.
Emergency granulopoiesis.
Manz MG, Boettcher S. Manz MG, et al. Among authors: boettcher s. Nat Rev Immunol. 2014 May;14(5):302-14. doi: 10.1038/nri3660. Epub 2014 Apr 22. Nat Rev Immunol. 2014. PMID: 24751955 Review.
Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.
Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Wolf MJ, et al. Among authors: boettcher s. Cancer Cell. 2012 Jul 10;22(1):91-105. doi: 10.1016/j.ccr.2012.05.023. Cancer Cell. 2012. PMID: 22789541 Free article.